Edition:
United Kingdom

Editas Medicine Inc (EDIT.OQ)

EDIT.OQ on NASDAQ Stock Exchange Global Select Market

35.26USD
8:04pm BST
Change (% chg)

$-1.20 (-3.29%)
Prev Close
$36.46
Open
$36.45
Day's High
$36.45
Day's Low
$35.09
Volume
129,623
Avg. Vol
335,630
52-wk High
$45.02
52-wk Low
$15.28

Chart for

About

Editas Medicine, Inc. is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly... (more)

Overall

Beta: --
Market Cap(Mil.): $1,043.82
Shares Outstanding(Mil.): 41.74
Dividend: --
Yield (%): --

Financials

  EDIT.OQ Industry Sector
P/E (TTM): -- 85.36 32.76
EPS (TTM): -3.19 -- --
ROI: -42.42 2.21 14.61
ROE: -63.35 3.85 16.34

BRIEF-Editas Medicine Reports Q1 Loss Per Share Of $0.67

* EDITAS MEDICINE ANNOUNCES FIRST QUARTER 2018 RESULTS AND UPDATE

03 May 2018

BRIEF-Editas Medicine Names James Mullen As Chairman Of Board

* EDITAS MEDICINE NAMES JAMES C. MULLEN AS CHAIRMAN OF THE BOARD OF DIRECTORS

28 Mar 2018

BRIEF-Editas Medicine Inc Files For Mixed Shelf Of Up To $150 Million – SEC Filing‍​

* EDITAS MEDICINE INC FILES FOR MIXED SHELF OF UP TO $150 MILLION – SEC FILING‍​ Source text (http://bit.ly/2GlXQp9) Further company coverage: (Reuters.Brief@thomsonreuters.com)

12 Mar 2018

BRIEF-Editas Medicine Q4 Loss Per Share $0.84

* EDITAS MEDICINE ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 RESULTS AND UPDATE

06 Mar 2018

BRIEF-Adverum Biotechnologies Extends Collaboration Agreement With Editas Medicine

* ANNOUNCES EXTENSION OF ITS COLLABORATION AGREEMENT WITH EDITAS MEDICINE INC

25 Jan 2018

Earnings vs. Estimates